A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Amyotrophic lateral sclerosis (ALS) is a ruthless neurodegenerative disease affecting the motor neuron system. Variability of disease progression and lack of refined readouts have limited the effectiveness of ALS clinical trials, making novel tools for patient stratification at trial recruitment, and better outcome measures, desperately needed in order to achieve therapeutic progress. Here, we investigate the potential of plasma cell-free microRNAs as biomarkers to predict ALS progression. Wedoi:10.1101/833079 fatcat:tggw24atvrgqpkooyxcko2wtla